Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

C3N-01488

— · cohortA1

74fb01c3-e41e-55a4-ad73-cd42c48ddaaa

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortA1
subtype
cohortA1
age_years
54.25598905

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.620
  • INTERFERON_GAMMA_RESPONSE+0.510
  • INFLAMMATORY_RESPONSE+0.330
  • IL6_JAK_STAT3_SIGNALING+0.310
  • ALLOGRAFT_REJECTION+0.300
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
  • TNFA_SIGNALING_VIA_NFKB+0.260
  • COMPLEMENT+0.210
  • PI3K_AKT_MTOR_SIGNALING+0.200
  • APOPTOSIS+0.190

Top 10 suppressed

  • WNT_BETA_CATENIN_SIGNALING-0.330
  • OXIDATIVE_PHOSPHORYLATION-0.290
  • MYC_TARGETS_V1-0.260
  • SPERMATOGENESIS-0.250
  • ESTROGEN_RESPONSE_LATE-0.240
  • G2M_CHECKPOINT-0.240
  • E2F_TARGETS-0.230
  • KRAS_SIGNALING_DN-0.230
  • ESTROGEN_RESPONSE_EARLY-0.220
  • PEROXISOME-0.220

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR10900571
melanoma-umap@29
——0.814
253612_S117
lung-landscapes@6
—cohortMD20.810
3SRR8518235
breast-umap@18
—D0.807
4SRR8518332
breast-umap@18
—D0.791
5SRR8518123
breast-umap@18
—D0.789
6TCGA-69-7978-01A-11R-2187-07
lung-landscapes@6
—cohortA10.788
7C3N-00433
lung-landscapes@6
—cohortMD20.786
8SRR8613789
breast-umap@18
—A0.782
930fdca7b-ecb1-4096-b2d2-41831f283ae1
colon-landscapes@1
——0.781
10C3N-03765
lung-landscapes@6
—cohortA10.781

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 19 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.620Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.510Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.330Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.310Inavolisib— uncovered
ALLOGRAFT_REJECTION0.300Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.280Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.260Inavolisib— uncovered
COMPLEMENT0.210Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.200Inavolisib— uncovered
APOPTOSIS0.190Idelalisib— uncovered
APICAL_JUNCTION0.150Inavolisib— uncovered
TGF_BETA_SIGNALING0.150Inavolisib— uncovered
UV_RESPONSE_DN0.130Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.120Idelalisib— uncovered
NOTCH_SIGNALING0.110Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.080Inavolisib— uncovered
IL2_STAT5_SIGNALING0.060Idelalisib— uncovered
COAGULATION0.030Binimetinib— uncovered
KRAS_SIGNALING_UP0.030Inavolisib— uncovered